Stoke Therapeutics (NASDAQ:STOK) Posts Quarterly Earnings Results

Stoke Therapeutics (NASDAQ:STOK) released its earnings results on Tuesday. The company reported ($0.97) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.22), FiscalAI reports. The business had revenue of $1.40 million for the quarter, compared to the consensus estimate of $5.32 million. Stoke Therapeutics had a net margin of 19.73% and a return on equity of 13.28%.

Stoke Therapeutics Stock Performance

STOK opened at $32.87 on Wednesday. The stock has a market capitalization of $1.88 billion, a price-to-earnings ratio of 49.06 and a beta of 1.07. The company has a fifty day moving average of $32.69 and a 200 day moving average of $29.89. Stoke Therapeutics has a fifty-two week low of $5.35 and a fifty-two week high of $40.22.

Insider Activity at Stoke Therapeutics

In other news, Director Adrian R. Krainer sold 33,243 shares of the stock in a transaction on Tuesday, March 10th. The shares were sold at an average price of $39.74, for a total value of $1,321,076.82. Following the sale, the director owned 283,302 shares of the company’s stock, valued at approximately $11,258,421.48. This represents a 10.50% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Arthur Tzianabos sold 4,355 shares of the business’s stock in a transaction that occurred on Tuesday, March 10th. The shares were sold at an average price of $40.00, for a total value of $174,200.00. Following the transaction, the insider owned 31,339 shares of the company’s stock, valued at $1,253,560. This trade represents a 12.20% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 38,203 shares of company stock valued at $1,517,541 in the last 90 days. 9.50% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Stoke Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the company. Janus Henderson Group PLC lifted its holdings in Stoke Therapeutics by 333.8% during the fourth quarter. Janus Henderson Group PLC now owns 1,450,933 shares of the company’s stock worth $46,031,000 after buying an additional 1,116,452 shares during the period. State Street Corp raised its position in shares of Stoke Therapeutics by 75.2% in the 4th quarter. State Street Corp now owns 2,498,049 shares of the company’s stock worth $79,288,000 after acquiring an additional 1,072,176 shares in the last quarter. Corient Private Wealth LLC purchased a new stake in shares of Stoke Therapeutics during the 2nd quarter worth $7,489,000. Wellington Management Group LLP lifted its stake in shares of Stoke Therapeutics by 438.2% during the 3rd quarter. Wellington Management Group LLP now owns 737,753 shares of the company’s stock worth $17,337,000 after purchasing an additional 600,687 shares during the last quarter. Finally, Polar Capital Holdings Plc boosted its position in Stoke Therapeutics by 49.8% during the third quarter. Polar Capital Holdings Plc now owns 1,323,470 shares of the company’s stock valued at $31,102,000 after purchasing an additional 439,824 shares in the last quarter.

Trending Headlines about Stoke Therapeutics

Here are the key news stories impacting Stoke Therapeutics this week:

• Positive Sentiment: Analysts raised targets and ratings — Needham raised its price target from $35 to $40 and maintains a “buy” rating; Wedbush raised its target from $36 to $38 and keeps an “outperform” rating, signaling continued analyst confidence and potential upside. Analyst Price Target Raises
• Neutral Sentiment: Company granted inducement stock options (58,650 options to six new hires effective March 16, 2026) — this helps recruit talent but adds potential future dilution. Inducement Grants Release
• Negative Sentiment: Quarterly results missed expectations — EPS of ($0.97) vs. consensus ($0.75) and revenue $1.4M vs. $5.32M expected. The revenue shortfall and wider EPS miss are the clearest drivers of downward pressure on the share price. Quarterly Earnings Report
• Negative Sentiment: Insider sale — Director Arthur A. Levin sold 605 shares at an average $36.80, reducing his holdings by ~12.5%. The sale is relatively small in dollar terms but may be interpreted negatively by some investors. SEC Form 4

Wall Street Analysts Forecast Growth

Several research firms have issued reports on STOK. Wedbush upped their price target on shares of Stoke Therapeutics from $36.00 to $38.00 and gave the company an “outperform” rating in a research report on Tuesday. Guggenheim started coverage on Stoke Therapeutics in a research note on Thursday, February 5th. They issued a “buy” rating and a $60.00 target price for the company. Canaccord Genuity Group increased their price objective on Stoke Therapeutics from $28.00 to $36.00 and gave the company a “buy” rating in a research note on Monday, January 5th. Weiss Ratings restated a “hold (c-)” rating on shares of Stoke Therapeutics in a report on Monday, December 29th. Finally, HC Wainwright increased their price target on shares of Stoke Therapeutics from $35.00 to $50.00 and gave the company a “buy” rating in a research report on Monday, December 15th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat.com, Stoke Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $39.83.

Stoke Therapeutics Company Profile

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.